Here are three things to know.
1. The agency approved Erleada to treat nonmetastatic prostate cancer that does not respond to hormone therapy.
2. Erleada represents the first FDA-approved treatment for this form of cancer.
3. In a recent clinical trial of 1,207 prostate cancer patients, Erleada reduced the risk of distant metastasis or death by 72 percent compared to a placebo.
4. Erleada’s list price will be about $10,920 per month, according to Reuters.
More articles on supply chain:
FDA greenlights Teligent’s topical steroid: 3 things to know
8 initiatives FDA would pursue under FY 2018 budget
FDA clears seizure-monitoring smartwatch
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.